Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t
about
Risk of cancer in diabetes: the effect of metforminSulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysisSulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusDiabetes mellitus and metformin in hepatocellular carcinomaMetformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-AnalysisInsulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studiesMetformin therapy and risk of cancer in patients with type 2 diabetes: systematic reviewAnti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysisMetformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysisMetformin in obesity, cancer and aging: addressing controversiesEffect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studiesMeta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysisMetformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Metformin and breast cancer risk: a meta-analysis and critical literature review.Metformin in cancer prevention and therapy.Syrosingopine sensitizes cancer cells to killing by metforminMetformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control studyCancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.Peroxisome proliferator-activated receptors and cancer: challenges and opportunitiesCancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.Clinical benefits of metformin in gynecologic oncology.Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysisInsulin therapy and cancer in type 2 diabetes.New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer.Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.Adiponectin improves NF-κB-mediated inflammation and abates atherosclerosis progression in apolipoprotein E-deficient mice.Safety of PPAR agonists.Metformin effects revisited.Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention.Metformin: a new option in cancer treatment.Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
P2860
Q21284807-B5624C12-8E2C-47A6-BB8A-10355E0E4943Q22241119-D4C82EA2-FD67-46C0-8834-3291E6D3EDD3Q24186660-35A1A36B-9394-45BD-B483-BC0FDAA140E5Q24197884-E5799515-E8F4-4CDA-8DF6-BA83CD59B823Q26741205-07AF4EA0-EFC6-4ABC-BAA0-973B2265C875Q26765139-B2AAA285-90CF-43CE-8DA3-5E7CD5DF9FB7Q26823071-68607CDF-A839-4625-8404-F26CE82D4596Q26850912-5E5ADAB8-6D10-4CCD-B4E5-5A5D6A8A1AE4Q27306002-072F1FF7-4409-42B2-8ABA-0E0B3646CF5CQ28069605-B655A346-1A25-4E42-9705-F1EC302383E6Q28480735-588AC4E9-A430-49EA-9DCD-44C4D0A70542Q28542914-28981184-368B-4F5B-B2E6-F870B4D2771AQ33672932-598442FD-88A5-498D-821C-BF2598C81914Q33748862-80112152-BA64-46E5-AAF6-4D8EBDF679DEQ33793812-32A9B0DB-AA25-4594-A824-D9A6AFAE6151Q34065266-10C88800-60FE-45F9-9271-49DC704920BCQ34135248-E94CEF39-868A-4408-9785-34B89D75141DQ34357389-6CB09FD5-73E3-4C6B-B156-45207A1C8160Q34357983-C7DA4866-851F-484F-8081-EE3120D9D87EQ34548130-6554D8DA-5185-4AD3-B6C6-D56845804E25Q34899291-6923C7EF-B2A2-40CE-8599-4D3B51FC9364Q35104958-0742051B-B220-4125-911D-0A8B92A509FBQ35189862-728B6E0B-8611-4ECF-899A-A7B7D0F5DDDAQ35210023-6E994A5C-DBC7-4615-8604-A647464F6B9BQ35842470-4B8AF792-17A2-4E3D-A2A2-7676160EB428Q35871269-C19E48E8-FCF1-4CE9-BC36-A4D018809F3FQ36136847-31295DEB-F4DC-4A31-B838-93D9FE20BD4DQ36247512-BAC58088-F99D-4CB2-A833-EA132076CAF4Q36417868-A5A5EAD9-F9AA-4115-A488-6A4F1237F90CQ36443863-0A7F09E7-5E34-472C-81CA-73A0A93C4DD7Q36524748-D0CC3FBA-AAE3-4CC6-8871-7CCC4848DE03Q36675844-8D53E32F-81F1-4438-A313-513299C3EF87Q36783775-30ED9A2C-0C64-4F02-A877-707F9B636AE3Q37554697-417D8D53-B279-4CE5-B365-579D59D3C35AQ37608817-8464BBDE-8618-4F66-A03C-0776AA97D946Q37890687-8B277797-F26A-4A7F-82D0-FCDCCEB97FA1Q38016107-3F981B4F-4EE7-4995-B646-1A80555878AEQ38033044-5BD1FFF8-8CB7-4078-9693-0745581E181BQ38079130-4705A34D-C16F-4515-83DA-211051900D24Q38080666-D1454751-8952-447F-A3A0-F87CA314C68D
P2860
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Experience of malignancies wit ...... caemia in Diabetes) clinical t
@ast
Experience of malignancies wit ...... caemia in Diabetes) clinical t
@en
Experience of malignancies wit ...... he randomised controlled ADOPT
@nl
type
label
Experience of malignancies wit ...... caemia in Diabetes) clinical t
@ast
Experience of malignancies wit ...... caemia in Diabetes) clinical t
@en
Experience of malignancies wit ...... he randomised controlled ADOPT
@nl
prefLabel
Experience of malignancies wit ...... caemia in Diabetes) clinical t
@ast
Experience of malignancies wit ...... caemia in Diabetes) clinical t
@en
Experience of malignancies wit ...... he randomised controlled ADOPT
@nl
P2093
P2860
P1433
P1476
Experience of malignancies wit ...... a in Diabetes) clinical trials
@en
P2093
ADOPT Study Group
H Beck-Nielsen
RECORD Steering Committee
P2860
P2888
P304
P356
10.1007/S00125-010-1804-Y
P577
2010-06-08T00:00:00Z
P5875
P6179
1017046673